Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS RECEIVABLE

v3.22.2.2
ACCOUNTS RECEIVABLE
9 Months Ended
Oct. 01, 2022
Receivables [Abstract]  
ACCOUNTS RECEIVABLE ACCOUNTS RECEIVABLE
Allowance for Doubtful Accounts
The Company reviews the estimates used to calculate the allowance for doubtful accounts on a quarterly basis.
The following table presents a rollforward of the allowance for doubtful accounts:
Nine Months Ended September
(In thousands) 2022 2021
Balance, December $ 11,705  $ 19,143 
Provisions for expected credit losses 2,116  (130)
Accounts receivable balances written off (1)
(1,069) (6,526)
Other (2)
(1,197) (633)
Balance, September $ 11,555  $ 11,854 
(1) Accounts receivable balances written off against the allowance were primarily due to the exit of our India business during 2021.
(2) Other primarily includes the impact of foreign currency translation and recoveries of amounts previously written off, none of which were individually significant.
Sale of Trade Accounts Receivable
The Company is party to an agreement with a financial institution to sell selected trade accounts receivable on a nonrecourse basis. Under this agreement, up to $377.5 million of the Company’s trade accounts receivable may be sold to the financial institution and remain outstanding at any point in time. The Company removes the sold balances from "accounts receivable, net" in its balance sheet at the time of sale. The Company does not retain any interests in the sold trade accounts receivable but continues to service and collect outstanding trade accounts receivable on behalf of the financial institution.
During the nine months ended September 2022 and September 2021, the Company sold total trade accounts receivable of $1,016.0 million and $943.2 million, respectively. As of September 2022, December 2021 and September 2021, $197.8 million, $170.6 million and $197.7 million, respectively, of the sold trade accounts receivable had been removed from the Company's balance sheets but remained outstanding with the financial institution.
The funding fees charged by the financial institution for this program are reflected in the Company's statements of operations within "other expense, net" and were $1.4 million and $3.0 million for the three and nine months ended September 2022, respectively, and $0.5 million and $1.4 million for the three and nine months ended September 2021, respectively. Net proceeds of this program are reflected as operating activities in the Company's statements of cash flows.